Specify a stock or a cryptocurrency in the search bar to get a summary
Novocure Ltd
NVCRNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. Address: No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Analytics
WallStreet Target Price
26.71 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures NVCR
Dividend Analytics NVCR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NVCR
Stock Valuation NVCR
Financials NVCR
Results | 2019 | Dynamics |